Background: Experimental and epidemiological evidence suggests that prolactin might play a role in the etiology of breast cancer. We analyzed the relationship of prediagnostic circulating prolactin levels with the risk of breast cancer by menopausal status, use of postmenopausal hormone replacement therapy (HRT) at blood donation, and by estrogen and progesterone receptor status of the breast tumors.
association was observed [OR Q4-Q1 = 0.70 (95% CI 0.48-1.03), P trend = 0.16]. There was no heterogeneity in the prolactin-breast cancer association by hormone receptor status of the tumor.
Conclusion:
Our study indicates that higher circulating levels of prolactin among the postmenopausal HRT users at baseline may be associated with increased breast cancer risk. Key words: breast cancer, prolactin levels, hormone replacement therapy, estrogen receptor, progesterone receptor, prospective cohort introduction The polypeptide hormone prolactin promotes the proliferation of breast epithelial cells, and in combination with progesterone promotes the differentiation of specialized structures-alveoli-that synthesize and secrete milk during lactation [1] . Associations of several breast cancer risk factors, such as nulli-parity and high mammographic breast density with increased serum prolactin concentrations, [2, 3] in combination with animal experimental data led to the hypothesis that elevated prolactin might promote breast tumor development [4, 5] .
One large and four very small prospective studies have previously addressed possible associations between circulating prolactin levels and breast cancer risk [4, [6] [7] [8] [9] . In the Nurses' Health Study (NHS), the only large-scale prospective study to date, a series of nested case-control studies indicated a modest positive risk association between serum prolactin concentrations and breast cancer risk among postmenopausal women and especially with the risk of estrogen receptor-positive (ER+) disease, but showed no significant associations among premenopausal women or with ER-negative breast cancer [4, 10] . The other four studies, which each included only small numbers of incident breast cancer cases (n = 20-173), showed no significant relationship between serum prolactin and breast cancer risk among either pre-or postmenopausal women [6] [7] [8] [9] and did not provide any information with regard to hormone receptor status of the tumors.
In this large case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we examined the association of prediagnostic serum levels of prolactin among pre-and postmenopausal women with subsequent risk of breast cancer, overall, by hormone receptor status of the tumor and by the use of postmenopausal hormone replacement therapy (HRT) at the time of blood donation. With a total of 2250 incident breast cancer cases, including 817 postmenopausal case subjects reporting HRT use at baseline, this is the second major prospective study to date on the relationships between prediagnostic prolactin levels and subsequent breast cancer risk.
study population and methods

the EPIC cohort
The EPIC cohort is based on 366 521 women and 153 457 men recruited between the years 1992 and 2000 in 10 European countries: Denmark, France, Germany, Greece, Italy, Norway, Spain, Sweden, The Netherlands, and the UK. Details on the subject recruitment, baseline data, and blood collection protocols have been reported previously [11] . In brief, anthropometric measurements and questionnaire data on diet, health status, reproductive and menstrual history, and medication use was collected at baseline. All EPIC study participants provided written consent for the use of questionnaire information and blood samples in research studies. Ethical approval for the nested case-control study reported here was obtained from the ethical review boards of International Agency for Research on Cancer (IARC) (Lyon, France) and from the local ethics committees in participating countries/study centers.
Details on the identification of vital status, breast cancer incidence, and information/quantification descriptions for the hormone receptor status of the tumors across the study centers were reported previously [11, 12] . For the present study, the closure date for follow-up was the last date of complete followup for both cancer incidence and vital status, which ranged from 2003 to 2006, depending on the study center. Sweden was not included in the analysis because independent studies were being completed on breast cancer risk and endogenous hormones [9] .
design of the nested case-control study General criteria for the inclusion of cases and matched controls into the study were that women could be clearly classified as being either pre-or postmenopausal at the time of blood donation, and did not have any previous diagnosis of cancer (except non-melanoma skin cancer). Women who were ≤42 years of age or reported having had at least nine menstrual periods in the last 12 months were classified as premenopausal. Women were classified as postmenopausal when they reported not having any menses over the past 12 months, when older than 55 years of age, or when reporting bilateral ovariectomy. Women aged 42 years or older whose questionnaire data on menopausal status were incomplete were not included to the present casecontrol study.
For each case-subject, one control subject closest to the case (based on matching criteria) with an available blood sample was chosen among appropriate risk sets consisting of all cohort members alive and free of cancer at the time of diagnosis of the index case. Matching criteria were the study recruitment center, menopausal status at blood donation, age at blood donation (±6 months), time at blood donation (±2 h), fasting status, phase of menstrual cycle [matching categories for premenopausal women: early follicular (days 0-7 of the cycle), late follicular (days 8-11), mid-cycle (days 12-16), early luteal (days 17-19), mid-luteal (days 20-24), late luteal (days 25+)], and current use of HRT at the time of blood donation (for postmenopausal women).
In total, 2271 invasive breast cancer case subjects and an equal number of control subjects were selected for the study. After exclusion of case or control subjects with missing prolactin measurements (n = 17) and with the prolactin value above detection range of the assay (more than 133 ng/ml, n = 4), 2250 incident cases and an equal number of controls remained for the analyses.
laboratory assays
The prolactin analyses were performed in the laboratory of the Division of Cancer Epidemiology at the German Cancer Research Centre and determined by immunoradiometric assay [IRMA (CT), IBL International GMBH, Germany] from blood taken at baseline. The detection range of the assay was 0.35-133 ng/ml. The same quality controls were included in each analytical batch. The mean inter-and intra-assay coefficients of variation were 4.62% and 2.17%, respectively.
statistical analyses
Conditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer occurrence, calculating ORs over the quartile levels and on a continuous log 2 scale of circulating prolactin. As circulating prolactin levels show variation over the menopausal status, the quartile cutoff points were calculated separately based on the control population of pre-and postmenopausal women. We a priori decided to adjust all the models for number of full-term pregnancies (0, 1, 2, 3, ≥4, missing), smoking status (current, never, previous, missing), and body mass index (continuous scale) due to modest variation in prolactin levels over these factors in healthy women. A more detailed description of the statistical analysis used in this study is described in supplementary Material, available at Annals of Oncology online. All P-values presented are two-sided and P < 0.05 was considered statistically significant. Statistical analyses were conducted using SAS software, version 9.2 (SAS Institute, Cary, NC).
results
This nested case-control study consisted of 2250 case subjects with incident, invasive breast cancer matched to an equal number of control subjects. A total of 1738 case-control pairs were sampled among women who could be unambiguously classified as being postmenopausal at blood donation, and 512 pairs were sampled among premenopausal women. For the premenopausal case-control pairs, the median age at blood donation (baseline) was 46. (Table 1) . A total of 817 postmenopausal case-control pairs were using HRT at the time they provided their blood sample. In linear regression analyses adjusted for matching factors, the number of full-term pregnancies, smoking status, and body mass index, our data showed significantly higher prolactin levels among premenopausal women when compared with postmenopausal women [adjusted geometric mean levels 7.87 (95% CI 7.4-8.3) versus 6.54 (95% CI 6.3-6.8) ng/ml], and among postmenopausal HRT users (especially among combined estrogenplus-progestin users) compared with non-users at baseline [adjusted geometric mean levels 6.72 (95% CI 6.4-7.1) versus 5.94 (95% CI 5.7-6.2) ng/ml]. In case-control comparisons, prolactin levels differed on average ∼3% between case and control subjects, with the greatest difference among postmenopausal women who used HRT at baseline (5.9%) (data not shown).
With regard to our risk models (logistic regression), as statistical tests indicated significant heterogeneity in the strength of the association between breast cancer and circulating prolactin levels by menopausal status at baseline (P het = 0.04), all statistical analyses were conducted separately for pre-and postmenopausal women. Among the premenopausal women, conditional logistic regression analyses adjusting for smoking status, number of full-term pregnancies, and body mass index suggest a negative association of serum prolactin levels with overall breast cancer risk, which was not statistically significant [OR Q4-Q1 = 0.70 (95% CI 0.48-1.03); P trend = 0.16] ( Table 2) . Among the postmenopausal women, there was a positive association of prolactin levels with breast cancer risk overall, with a statistically significant OR of 1.29 (95% CI 1.05-1.58) in the highest quartile of prolactin, but no statistically significant trend based on prolactin as a continuous log 2 variable (P trend = 0.09). When the analyses were stratified further by baseline HRT use, statistically Stratifying the analyses by hormone receptor status of the tumor, there was no evidence of heterogeneity in the prolactin-breast cancer relationship by tumor subtype, overall or in strata of users or non-users of HRT (Table 3) . Among postmenopausal women using combined estrogen-plus-progestin HRT, the relative risk appeared to be more pronounced for ER + tumors [OR log2 = 1.27 (95% CI 1.03-1.57), P trend = 0.03, on a continuous log 2 scale, n = 338/425] than among users of estrogens only therapy [OR log2 = 1.06 (95% CI 0.72-1.58), P trend = 0.77, n = 103/206], although the test for statistical heterogeneity was not statistically significant (P het = 0.44) (data not shown).
In subgroup analyses, statistical tests showed no evidence of heterogeneity in the strength of the association with overall breast cancer risk by lag time until breast cancer diagnosis (supplementary Table S1 , available at Annals of Oncology online), and overall, there was also no significant heterogeneity by age at tumor diagnosis in either pre-or postmenopausal women (data not shown). Among the postmenopausal women using HRT at baseline, however, circulating levels of prolactin were significantly associated with breast cancer diagnosed above the median age (61 years) within this subgroup [OR log2 = 1.46 (95% CI 1.18-1.80), P trend = 0.0004, n = 370 sets], but not with breast cancer diagnosed at a younger age [OR log2 = 0.95 (95% CI 0.76-1.19), P trend = 0.65, n = 447 sets] (P het = 0.01) (data not shown).
Complementary statistical analyses showed no evidence for major confounding or interaction effects by other reproductive and lifestyle factors, or by levels of the other endogenous hormones (data not shown). Furthermore, sensitivity analyses in which the first 2 years of follow-up were excluded did not show any major difference in risk estimates compared with the full dataset.
discussion
In this large prospective study, we observed a statistically significant heterogeneity in the association of prolactin levels with breast cancer risk between women who were either pre-or postmenopausal at the time of blood donation. Among postmenopausal women, there was a significant positive association of prolactin levels with overall breast cancer risk; however, this increase in risk seemed to be confined to women who used HRT at the time of blood donation. Among premenopausal women, there was a statistically non-significant inverse association of prolactin with breast cancer risk. Our data showed no evidence for heterogeneity in the relationship of prolactin levels with risk of hormone receptor positive or negative breast tumors.
Our findings show partial agreement with those from the Nurses' Health Study cohorts I and II, in which a series of nested case-control studies were conducted to address the relationship of serum prolactin levels with breast tumor development [4, 10] that included up to 3421 breast cancer cases [4] . In the Nurses' studies, using data based on only the first 10 years of prospective follow-up (comparable to the follow-up time our present study) with 2468 breast cancer (of whom 1023 among pre-and 1445 among postmenopausal women) and 4021 control subjects, there was a positive association between serum prolactin and overall breast cancer risk among postmenopausal women, and no association among women who were premenopausal at the time of blood draw (P het = 0.01). Our observations are similar to these findings. However, contrary to our [4] . In our data, there was no evidence for heterogeneity of the prolactin-breast cancer association by receptor status. In several other, much smaller prospective studies, the heterogeneity of relationships of prolactin with breast cancer risk by receptor status was not addressed [6] [7] [8] [9] . The observed associations between circulating prolactin and subsequent breast cancer risk, both in our study and in the Nurses' cohorts, were of a modest magnitude compared with the associations reported for other endogenous hormones, such as testosterone and estradiol, with relative risk estimates up to 2.5 for top versus bottom tertile levels [12] . Nonetheless, a vast body of evidence from animal and in vitro studies supports the involvement of prolactin in breast cancer development. Especially in combination with the ovarian steroid hormones estradiol and progesterone, prolactin has effects on normal epithelial cell expansion, ductal side branching of the breast during puberty, and formation of lobuloalveolar structures during pregnancy [1] . Furthermore, prolactin and progesterone have synergic roles in inducing cell growth and proliferative activity in the terminal duct-lobular units of the breast-the site of origin of most breast cancers-and evidence is accumulating for crosstalk between progesterone, prolactin, and their receptor signaling pathways in normal and malignant breast cells [13] [14] [15] .
We observed a more pronounced association between circulating prolactin and breast cancer among postmenopausal women who were using HRT at the time of blood donation, compared with the association among HRT non-users. Given the well-documented biological synergy between prolactin and progesterone, it is striking that our data indicated a significant association of prolactin with the risk of receptor-positive tumors among women using combined estrogen-plus-progestin HRT, but not among the users of estrogen-only. However, only a reduced number of women in our study had detailed information about the types of HRT used, and the statistical test for heterogeneity between estrogen-plus-progestin users and estrogen-only users was not statistically significant. Furthermore, in the Nurses' cohorts associations of prolactin with breast cancer risk were reported to be relatively independent of exogenous hormone use at the time of blood donation (P het = 0.65) [4, 10] . At the time the NHS was conducted, most women were on estrogen only HRT and relatively few were on combined estrogenplus-progestin HRT ( personal communication), which may explain why NHS did not see a difference by HRT use.
Major strengths of our study are its prospective design and the large number of incident cases with the information on hormone receptor status of the tumor, which allowed subgroup analyses describing risk associations by menopausal status, postmenopausal HRT use, and receptor status of the tumor. A limitation of our study is that for each woman we had prolactin measurements for only one blood sample, which may limit interpretations about women's average prolactin levels over time periods longer than 5-10 years [4, 16] . Furthermore, although classification of breast cancer outcomes by receptor status has been shown to be relatively robust and to have only moderate dependence on the assay used, especially for medium-and high-expressing tumors [17] , staining for receptor status was performed in different laboratories both within and across EPIC centers, and this may have led to some misclassification by receptor status. Finally, in spite of the large study size (a total of 2250 matched case-control pairs), our study still had relatively limited numbers of case subjects for hormone receptor negative tumors within strata of menopausal status and postmenopausal HRT use, and thus the statistical power for detecting associations of prolactin with risk in these subgroups was limited.
conclusions Our study shows that higher circulating levels of prolactin among the postmenopausal women who used HRT at baseline are associated with increased breast cancer risk. In contrast, statistically non-significant inverse association of premenopausal prolactin levels and subsequent breast cancer risk was seen. Our data did not show any heterogeneity in the prolactin-breast cancer association by hormone receptor status of the tumor among either pre-or postmenopausal women.
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